Relevant bibliographies by topics / Sacubitril

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Sacubitril'

Author: Grafiati
Published: 11 September 2021
Last updated: 30 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sacubitril.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Sacubitril"

1

Ryazanov, Alexey S., Evgenia V. Shikh, Konstantin I. Kapitonov, Mariya V. Makarovskaya, and Alexey A. Kudryavtsev. "The Effect of Angiotensin Receptor Inhibitors and Neprilysin on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction." Annals of the Russian academy of medical sciences 76, no. 3 (2021): 298–306. http://dx.doi.org/10.15690/vramn1526.

Full text
Abstract:
Background. Compared with enalapril, sacubitril/valsartan reduces mortality from cardiovascular diseases and the number of hospitalizations for heart failure in patients with heart failure and reduced ejection fraction (HFrEF). These benefits may be related to effects on hemodynamics and cardiac remodeling. The aim of the study is to determine the effect of sacubitril/valsartan on aortic stiffness and cardiac remodeling compared with enalapril in HFrEF. Materials and methods. In this long-term outpatient study, 100 patients with HFrEF received sacubitril/valsartan or enalapril. The primary end
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Ting, Jin-lian Cai, and Jie Yu. "Sacubitril/valsartan-induced liver injury: A case report and literature review." Medicine 102, no. 32 (2023): e34732. http://dx.doi.org/10.1097/md.0000000000034732.

Full text
Abstract:
Rationale: Sacubitril/valsartan (Entresto) is the first drug approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adult patients. There have been no reports of hepatotoxicity secondary to sacubitril/valsartan administration. Here, we report the first case of severe liver injury caused by sacubitril/valsartan. Patient concerns: A 90-year-old female patient taking sacubitril/valsartan was admitted due to chronic heart failure. Subsequently, the patient developed serious liver injury with increased hepatic transaminases. Diagnosis: Drug-induced liver i
APA, Harvard, Vancouver, ISO, and other styles
3

Alves-Lopes, Rhéure, Augusto C. Montezano, Karla B. Neves, et al. "Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension." Hypertension 78, no. 3 (2021): 604–16. http://dx.doi.org/10.1161/hypertensionaha.121.17041.

Full text
Abstract:
Combined inhibition of NEP (neutral endopeptidase) and ACE (angiotensin-converting enzyme), without unwanted effects, remains an attractive therapeutic strategy in cardiovascular medicine. Omapatrilat, a dual NEP inhibitor–ACE inhibitor, was a promising antihypertensive drug but failed in trials due to angioedema, an effect possibly caused by inhibition of both the N- and C-domains of ACE. Here, we aimed to determine whether lisinopril-tryptophan (lisW-S), a C-domain specific ACE inhibitor that preserves the N-domain catalytic activity, together with sacubitril (NEP inhibitor), differentially
APA, Harvard, Vancouver, ISO, and other styles
4

Rakugi, Hiromi, Kazuomi Kario, Masako Yamaguchi, Takayoshi Sasajima, Hiromi Gotou, and Jack Zhang. "Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study." Hypertension Research 45, no. 5 (2022): 824–33. http://dx.doi.org/10.1038/s41440-021-00819-7.

Full text
Abstract:
AbstractThis phase III study assessed the efficacy and safety of sacubitril/valsartan compared with those of olmesartan in Japanese patients with essential hypertension. Patients (n = 1161, aged ≥20 years) with mild to moderate hypertension (mean sitting systolic blood pressure [msSBP] ≥150 to <180 mmHg) were randomized to receive sacubitril/valsartan 200 mg (n = 387), sacubitril/valsartan 400 mg (n = 385), or olmesartan 20 mg (n = 389) once daily for 8 weeks. The primary assessment was a reduction in msSBP from baseline with sacubitril/valsartan 200 mg vs. olmesartan 20 mg at Week 8. Secon
APA, Harvard, Vancouver, ISO, and other styles
5

Maslov, Mikhail Y., Stephan Foianini, Dita Mayer, Michael V. Orlov, and Mark A. Lovich. "Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure." American Journal of Physiology-Heart and Circulatory Physiology 316, no. 2 (2019): H289—H297. http://dx.doi.org/10.1152/ajpheart.00579.2018.

Full text
Abstract:
Simultaneous neprilysin inhibition (NEPi) and angiotensin receptor blockade (ARB) with sacubitril/valsartan improves cardiac function and exercise tolerance in patients with heart failure. However, it is not known whether these therapeutic benefits are primarily due to NEPi with sacubitril or ARB with valsartan or their combination. Therefore, the aim of the present study was to investigate the potential contribution of sacubitril and valsartan to the benefits of the combination therapy on left ventricular (LV) function and exercise tolerance. Heart failure was induced by volume overload via p
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Zhulu, Chuan Zhang, Yuxi Zhu, Diansa Gao, Min Mao, and Zhong Zuo. "Sacubitril/valsartan can improve the cardiac function in heart failure patients with a history of cancer: An observational study." Medicine 103, no. 12 (2024): e37613. http://dx.doi.org/10.1097/md.0000000000037613.

Full text
Abstract:
Sacubitril/Valsartan, the combination of angiotensin receptor inhibitor and neprilysin inhibitor, is now becoming the class 1 recommendation for HFrEF. Some studies have shown the positive effect of Sacubitril/Valsartan on HFrEF cancer patients, while there is devoid of evidence about the effect of this drug in aged cancer patients with HFmrEF and HFpEF. By searching the patients with a diagnosis of both cancer and Heart failure (HF) over 65, the patients who had received treatment with Sacubitril/Valsartan were selected as the candidates for Sacubitril/Valsartan group, and the patients who ha
APA, Harvard, Vancouver, ISO, and other styles
7

Badreldin, Hisham A., Nasser Aldosari, Lama Alnashwan, et al. "What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies." Journal of Cardiovascular Development and Disease 9, no. 2 (2022): 54. http://dx.doi.org/10.3390/jcdd9020054.

Full text
Abstract:
Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF study in 2014. Therefore, for patients with HFrEF, worldwide recommendations have been reformed to include sacubitril/valsartan. In addition, sacubitril/valsartan has been investigated in other cardiovascular disease states, such as patients with heart failure and preserved ejection fraction (HFpEF) and following myocardial infarction (M
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Wei, Jin Zhang, Jie Yan, et al. "P148 EFFICACY AND SAFETY OF SACUBITRIL/ALLISARTAN FOR THE TREATMENT OF PRIMARY HYPERTENSION: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY." Journal of Hypertension 42, Suppl 3 (2024): e112-e113. http://dx.doi.org/10.1097/01.hjh.0001063464.65046.75.

Full text
Abstract:
Background: This randomized, double-blind, phase 3 study assessed the efficacy and safety of sacubitril/allisartan, an angiotensin receptor neprilysin inhibitor, compared with olmesartan in Chinese patients with mild to moderate hypertension. Methods: Eligible patients aged 18-75 years (n=1197) with mild to moderate hypertension were randomized to receive sacubitril/allisartan 240 mg (n=399), sacubitril/allisartan 480 mg (n=399), or olmesartan 20 mg (n=399) once daily for 12 weeks. Patients who completed the 12-week treatment then received another 12-week extended treatment (n=1084) and 28-wee
APA, Harvard, Vancouver, ISO, and other styles
9

Zhang, Wei, Jin Zhang, Jie Yan, et al. "EFFICACY AND SAFETY OF SACUBITRIL/ALLISARTAN FOR THE TREATMENT OF PRIMARY HYPERTENSION: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY." Journal of Hypertension 42, Suppl 1 (2024): e45. http://dx.doi.org/10.1097/01.hjh.0001019708.19000.e1.

Full text
Abstract:
Objective: This randomized, double-blind, phase 3 study assessed the efficacy and safety of sacubitril/allisartan, an angiotensin receptor neprilysin inhibitor, compared with olmesartan in Chinese patients with mild to moderate hypertension. Design and method: Eligible patients aged 18-75 years (n=1197) with mild to moderate hypertension were randomized to receive sacubitril/allisartan 240 mg (n=399), sacubitril/allisartan 480 mg (n=399), or olmesartan 20 mg (n=399) once daily for 12 weeks. Patients who completed the 12-week treatment then received another 12-week extended treatment (n=1084) a
APA, Harvard, Vancouver, ISO, and other styles
10

Sciatti, Edoardo, Michele Senni, Carlo M. Lombardi, Mauro Gori, and Marco Metra. "Sacubitril/valsartan." Journal of Cardiovascular Medicine 19, no. 9 (2018): 473–79. http://dx.doi.org/10.2459/jcm.0000000000000687.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Sacubitril"

1

SPADAFORA, EMANUELE. "ACUTE AND PROLONGED EFFECT OF NEW TREATMENTS (LEVOSIMENDAN AND SACUBITRIL/VALSARTAN) IN HEART FAILURE: AN HOLISTIC EVALUATION." Doctoral thesis, Università degli Studi di Milano, 2019. http://hdl.handle.net/2434/695162.

Full text
Abstract:
Alveolar-capillary membrane evaluated by carbon monoxide diffusion (DLCO) plays an important role in heart failure (HF). Surfactant Proteins (SPs) have also been suggested as a worthwhile marker. In acute HF, Levosimendan improves pulmonary hemodynamics and reduces lung fluids but associated SPs and DLCO changes are unknown. Sixty-five acute HF patients underwent spirometry, cardiopulmonary exercise test (CPET) and SPs determination before and after Levosimendan. Levosimendan caused natriuretic peptide-B (BNP) reduction, peakVO2 increase and VE/VCO2 slope reduction. Spirometry improved but DLC
APA, Harvard, Vancouver, ISO, and other styles
2

NUGARA, Cinzia. "Effetti della Terapia con Sacubitril/Valsartan sulla Capacità di Esercizio dei pazienti con Scompenso Cardiaco a Frazione di Eiezione Ridotta (HFrEF) nel Follow-up a Breve, Medio e Lungo Termine e Ruolo della percentuale di Delayed Enhancement (DE) alla Risonanza Magnetica Cardiaca (CMR) sulla risposta alla terapia: uno Studio Multicentrico." Doctoral thesis, Università degli Studi di Palermo, 2021. http://hdl.handle.net/10447/477048.

Full text
Abstract:
Introduzione: La terapia con Sacubitril/Valsartan nei pazienti con scompenso cardiaco a frazione di eiezione ridotta (HFrEF) si è dimostrata superiore alla singola terapia con Enalapril nella riduzione del rischio di morte ed ospedalizzazione per scompenso cardiaco. Obiettivo del presente studio è stato quello di valutare, nei pazienti con HFrEF, gli effetti della terapia con sacubitril/valsartan sulla capacità di esercizio valutata mediante Test Cardiorespiratorio e l’eventuale correlazione con il grado di fibrosi miocardica valutata mediante Risonanza Magnetica Cardiaca (CMR). Metodi: E’ s
APA, Harvard, Vancouver, ISO, and other styles
3

Sebastião, Mariana Rocha de Sá. "Remodelamento reverso do ventrículo esquerdo numa população de mundo real com insuficiência cardíaca." Master's thesis, 2020. http://hdl.handle.net/10316/97771.

Full text
Abstract:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina<br>Background: O remodelamento reverso do ventrículo esquerdo (RRVE) é induzido pelas terapêuticas modificadoras de prognóstico prévias ao antagonista dos recetores da angiotensina II – inibidor da neprisilina (ARNI), e está associado a melhoria de prognóstico em doentes com insuficiência cardíaca com fração de ejeção reduzida (ICFEr). O estudo PARADIGM-HF provou superioridade do sacubitril/valsartan em relação ao enalapril, mas a presença de RRVE nesta terapêutica permanece não avaliada. Métodos: Foi realizad
APA, Harvard, Vancouver, ISO, and other styles
4

Pereira, Gonçalo Lopes Martins e. "Safety and tolerability of sacubitril-valsartan : a systematic review and meta-analysis." Master's thesis, 2020. http://hdl.handle.net/10451/46764.

Full text
Abstract:
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2020<br>Introdução O Sacubitril-valsartan é um fármaco recente que já tem um papel importante na gestão da insuficiência cardíaca. Deste modo, realizámos uma revisão sistemática e meta-análise de ensaios clínicos randomizados (ECR) para sintetizar a evidência disponível referente à segurança e tolerabilidade do sacubitril-valsartan. Métodos Fizemos uma pesquisa procurando ECRs com doentes sob terapêutica com sacubitril-valsartan para qualquer patologia médica, comparando com a terapêuti
APA, Harvard, Vancouver, ISO, and other styles
5

Pais, Vítor Hugo de Matos. "LCZ696 (Sacubitril/Valsartan) Como Nova Abordagem Farmacológica da Insuficiência Cardíaca Crónica Sintomática." Master's thesis, 2017. http://hdl.handle.net/10400.6/8094.

Full text
Abstract:
A Insuficiência Cardíaca apresenta-se como uma das grandes epidemias do século XXI, com especial prevalência em idosos. Trata-se de um síndrome clínico complexo, associado a diversas co-morbilidades, e de diagnóstico difícil, sendo necessário um elevado índice de suspeição, pois muitas vezes a sintomatologia do doente surge já numa fase avançada da patofisiologia da doença. A abordagem da Insuficiência Cardíaca Crónica sintomática com fração de ejeção reduzida pode ser bastante desafiante face à complexidade que constitui o síndrome, sendo que nos últimos anos têm sido realizadas investigações
APA, Harvard, Vancouver, ISO, and other styles
6

Cabral, Joana Maria Teixeira. "Sacubitril/Valsartan in everyday clinical practice: the experience of a heart failure clinic." Master's thesis, 2020. https://hdl.handle.net/10216/128869.

Full text
Abstract:
Objetivos: O ensaio PARADIGM-HF estabeleceu a superioridade do sacubitril/valsartan (Sac/Val) sobre a inibição da Enzima Conversora da Angiotensina no tratamento da Insuficiência Cardíaca com Fração de Ejeção Reduzida (IC-FER). Neste estudo, caracterizamos os desafios da implementação do sacubitril/valsartan na prática clínica real. Métodos e resultados: Analisamos os registos clínicos dos doentes com IC-FER seguidos na clínica de Insuficiência Cardíaca e Transplante de um hospital terciário português em 2018 (n=240). Foram quantificados o número de candidatos a Sac/Val, o número de doentes a
APA, Harvard, Vancouver, ISO, and other styles
7

Cabral, Joana Maria Teixeira. "Sacubitril/Valsartan in everyday clinical practice: the experience of a heart failure clinic." Dissertação, 2020. https://hdl.handle.net/10216/128869.

Full text
Abstract:
Objetivos: O ensaio PARADIGM-HF estabeleceu a superioridade do sacubitril/valsartan (Sac/Val) sobre a inibição da Enzima Conversora da Angiotensina no tratamento da Insuficiência Cardíaca com Fração de Ejeção Reduzida (IC-FER). Neste estudo, caracterizamos os desafios da implementação do sacubitril/valsartan na prática clínica real. Métodos e resultados: Analisamos os registos clínicos dos doentes com IC-FER seguidos na clínica de Insuficiência Cardíaca e Transplante de um hospital terciário português em 2018 (n=240). Foram quantificados o número de candidatos a Sac/Val, o número de doentes a
APA, Harvard, Vancouver, ISO, and other styles
8

Syu, Jhen-Yang, and 許振揚. "Optical Mapping Analysis Software Development--- Based on Myocardial Dynamic Electrical Conduction and Effects of Prevention of Arrhythmia with Sacubitril/Valsartan." Thesis, 2019. http://ndltd.ncl.edu.tw/handle/r84s42.

Full text
Abstract:
碩士<br>國立交通大學<br>生醫工程研究所<br>107<br>Ventricular arrhythmia accounts for 80% of sudden cardiac arrest. Although arrhythmia may occur in all ages, it is more common in the elderly. And the previous studies have shown that the arrhythmia was associated with the propagation of the electrodynamics. When the SA Node triggers the electrical signal to cardiomyocytes, the electrical conduction will cause the atrium and ventricle contraction to pump the blood to the whole body. Therefore, the disorder electrodynamics may affect the function of the myocardium and induce arrhythmia. Also, there were studies
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Sacubitril"

1

Paneni, Francesco, and Massimo Volpe. Co-morbidity (HFrEF and HFpEF): hypertension. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198784906.003.0415_update_001.

Full text
Abstract:
Hypertensive heart disease is a major cause of heart failure (HF) and mortality. Hypertension precedes HF occurrence in 75% of cases, and carries a sixfold increase in HF risk as compared to non-hypertensive individuals. Most importantly, a minority of patients survive 5 years after the onset of hypertensive HF. In hypertensive patients, the heart may present different patterns of adaptive remodelling: concentric remodelling, concentric hypertrophy, and eccentric hypertrophy. Although most hypertensive patients are at high risk of developing concentric hypertrophy, a growing proportion of subj
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Sacubitril"

1

Khder, Yasser, Victor Shi, John J. V. McMurray, and Martin P. Lefkowitz. "Sacubitril/Valsartan (LCZ696) in Heart Failure." In Heart Failure. Springer International Publishing, 2016. http://dx.doi.org/10.1007/164_2016_77.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dhiraj, Kumar, and Himansu Bhusan Samal. "Development of stability indicating RP-HPLC method for simultaneous estimation of sacubitril and valsartan in pure and pharmaceutical dosage form." In Advancement in Animal Handling and Generative AI for Pre-clinical Studies. CRC Press, 2025. https://doi.org/10.1201/9781003672869-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Seferović, Petar M., Michele Senni, Marija Polovina, and Andrew JS Coats. "Angiotensin II receptor–neprilysin inhibitor." In The ESC Textbook of Heart Failure, edited by Petar M. Seferović, Andrew J. S. Coats, Gerasimos Filippatos, Stefan D. Anker, Johann Bauersachs, and Giuseppe Rosano. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780198891628.003.0042.

Full text
Abstract:
Abstract Sacubitril/valsartan is the first-in-class angiotensin receptor–neprilysin inhibitor (ARNI) that combines the effects of potentiating the activity of the natriuretic peptide (NP) system with counteracting the increased activity of angiotensin II, via inhibition of the neutral endopeptidase neprilysin, combined with blockade of the angiotensin II type 1 receptor. In the PARADIGM-HF trial that recruited ambulatory patients with heart failure with reduced ejection fraction (HFrEF), sacubitril/valsartan was associated with a 20% lower risk of cardiovascular mortality or heart failure (HF)
APA, Harvard, Vancouver, ISO, and other styles
4

Santos, Giulia Racanelli de Ferreira, and Renata Barreiros de Lacerda Siqueira. "SACUBITRIL/VALSARTANA UM NOVO OLHAR SOBRE A INSUFICIÊNCIA CARDÍACA." In Ciências médicas: Campo teórico, métodos, aplicabilidade e limitações 4. Atena Editora, 2021. http://dx.doi.org/10.22533/at.ed.88021080717.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ferreira, João Pedro, and Patrick Rossignol. "Renin–angiotensin system and neprilysin." In ESC CardioMed. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0031.

Full text
Abstract:
The advent of drugs able to modulate the renin–angiotensin system (RAS), and more recently the neprilysin inhibitor sacubitril in combination with a RAS blocker, has improved the outcome of many cardiovascular and renal conditions. In particular, heart failure, post-myocardial infarction, and hypertension are the cardiovascular clinical syndromes in which RAS inhibition (and in heart failure, in combination with neprilysin inhibition) has greatly improved morbidity and mortality. This chapter aims to provide an appraisal of RAS and neprilysin inhibitors regarding their pharmacological properti
APA, Harvard, Vancouver, ISO, and other styles
6

Ferreira, João Pedro, and Patrick Rossignol. "Renin–angiotensin system and neprilysin." In ESC CardioMed. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0031_update_001.

Full text
Abstract:
The advent of drugs able to modulate the renin–angiotensin system (RAS), and more recently the neprilysin inhibitor sacubitril in combination with a RAS blocker, has improved the outcome of many cardiovascular and renal conditions. In particular, heart failure, post-myocardial infarction, and hypertension are the cardiovascular clinical syndromes in which RAS inhibition (and in heart failure, in combination with neprilysin inhibition) has greatly improved morbidity and mortality. This chapter aims to provide an appraisal of RAS and neprilysin inhibitors regarding their pharmacological properti
APA, Harvard, Vancouver, ISO, and other styles
7

Rosano, Giuseppe, Gerasimos Filippatos, and Randall Starling. "New and emerging therapies in heart failure." In The ESC Textbook of Heart Failure, edited by Petar M. Seferović, Andrew J. S. Coats, Gerasimos Filippatos, Stefan D. Anker, Johann Bauersachs, and Giuseppe Rosano. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780198891628.003.0052.

Full text
Abstract:
Abstract The treatment of heart failure (HF) has substantially changed over the last decades, owing to the introduction of new drug classes. Improved understanding of HF as a disorder of circulatory haemodynamics, neurohormonal imbalance, pathological cardiac remodelling, and increased arrhythmogenic instability led to the development of novel treatments with efficacy in reducing morbidity and mortality, particularly in patients with reduced ejection fraction. These treatments included vasodilator therapy with hydralazine/isosorbide dinitrate combination and the ushering of drugs correcting th
APA, Harvard, Vancouver, ISO, and other styles
8

Chavan, Rahul B., and Nalini R. Shastri. "Overview of Multicomponent Solid Forms." In Alternative Pain Management. IGI Global, 2020. http://dx.doi.org/10.4018/978-1-7998-1680-5.ch004.

Full text
Abstract:
Multi-drug therapy involves the simultaneous or sequential administration of two or more drugs with similar or different mechanisms of action and is efficient in combating various ailments such as cancer, diabetes, and rheumatoid arthritis. It has emerged advantageous due to larger therapeutic benefits, an increase in patient compliance, lower administrative costs, and reduced number of prescriptions. In the recent past, the clinical success of the Novartis product Entresto (sacubitril, disodium valsartan and water) and Esteve product E-58425 (tramadol and celecoxib) has boosted the developmen
APA, Harvard, Vancouver, ISO, and other styles
9

Cikes, Maja, and Scott D. Solomon. "HFpEF treatment: pharmacological therapy." In ESC CardioMed. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0435.

Full text
Abstract:
Heart failure with preserved ejection fraction (HFpEF) is a diverse syndrome characterized by signs and symptoms of heart failure with relatively preserved ejection fraction. Despite the established efficacy of numerous classes of drugs and devices in heart failure with reduced ejection fraction, no specific therapy has yet proven to reduce morbidity and mortality in HFpEF. Currently, treatment of HFpEF remains empiric, and includes diuretic therapy for decongestion, treatment of hypertension, diagnosis and treatment of ischaemia, rate control for atrial fibrillation, and treatment of co-morbi
APA, Harvard, Vancouver, ISO, and other styles
10

Cikes, Maja, and Scott D. Solomon. "Heart failure with preserved ejection fraction." In ESC CardioMed. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0435_update_001.

Full text
Abstract:
Heart failure with preserved ejection fraction (HFpEF) is a diverse syndrome characterized by signs and symptoms of heart failure with relatively preserved ejection fraction. Despite the established efficacy of numerous classes of drugs and devices in heart failure with reduced ejection fraction, no specific therapy has yet proven to reduce morbidity and mortality in HFpEF. Currently, treatment of HFpEF remains empiric, and includes diuretic therapy for decongestion, treatment of hypertension, diagnosis and treatment of ischaemia, rate control for atrial fibrillation, and treatment of co-morbi
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Sacubitril"

1

Ekart, Robert, Nejc Piko, Luka Varda, Tadej Petreski, Sebastjan Bevc, and Radovan Hojs. "The role of sacubitril/valsartan in patients with advanced chronic kidney disease and heart failure." In 7th International Congress of Cardionephrology KARNEF 2025. Punta Niš, 2025. https://doi.org/10.46793/karnef25.136e.

Full text
Abstract:
Chronic kidney disease and heart failure (HF) are closely related conditions that often coexist and complicate each other. Both conditions can exacerbate disease progression and influence treatment strategies. Angiotensin receptor- neprilysin inhibitors (ARNIs) are playing an increasingly important role in the treatment of HF. ARNIs combine two mechanisms of action: sacubitril is a neprilysin inhibitor that enhances natriuretic peptides, resulting in vasodilation, diuresis and reduced cardiac workload; valsartan is an angiotensin II receptor blocker that reduces the effects of the renin-angiot
APA, Harvard, Vancouver, ISO, and other styles
2

Maurer, J., R. Mirchin, J. A. C. Rhee, and A. Al-Ghrairi. "Unexpected Case of Sacubitril-Valsartan Induced Brash Syndrome." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3500.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rizzo, María Antonella, María Concepción García, Sandra Izquierdo, et al. "ENTEROPATIA POR ENTRESTO (SACUBITRIL/VALSARTAN) REPORTE DE UN CASO." In 45 Congreso Nacional de la Sociedad Española de Endoscopia Digestiva. Grupo Pacífico, 2023. http://dx.doi.org/10.48158/seed2023.p109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tardy, C., F. Plassart, and JL Pons. "4CPS-026 The sacubitril-valsartan association: from theory to practice." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jovanovic, Jelena Dorovic, Zoran Markovic, Mihajlo Kokanovic, Nenad Filipovic, and Marijana Stanojevic. "Inhibitory potency of Valsartan/Sacubitril drug combination: molecular docking simulations." In 2021 IEEE 21st International Conference on Bioinformatics and Bioengineering (BIBE). IEEE, 2021. http://dx.doi.org/10.1109/bibe52308.2021.9635185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Soto, CM Valencia, J. Pastor Hurtado, MD Toscano Guzmán, et al. "4CPS-025 Suitability of sacubitril valsartan prescriptions in a health management area." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Enríquez Olivar, L., AM López González, S. Izquierdo Muñoz, E. Queipo García, and MT Sánchez Sánchez. "6ER-005 Use of sacubitril/valsartan in patients with chronic heart failure." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.602.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dimarco, Anthony, Paul Haydock, Andrew Flett, et al. "94 Real-world use of sacubitril-valsartan in the south of England." In Abstracts from the British Cardiovascular Society Annual Conference 2020. BMJ Publishing Group Ltd and British Cardiovascular Society, 2020. http://dx.doi.org/10.1136/heartjnl-2020-bcs.94.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Aparicio Peñacona, R., A. Oterino Manzanas, JC Garcia Casanueva, AM Lopez Gonzalez, L. Enriquez Olivar, and MJ Otero. "4CPS-041 Sacubitril/valsartan prescription practice in patients with chronic heart failure." In 26th EAHP Congress, Hospital pharmacists – changing roles in a changing world, 23–25 March 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/ejhpharm-2022-eahp.86.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rajkumar, A., J. Lemonnier, M. Gautier, JL Georges, F. Samdjee, and C. Courtin. "4CPS-023 Sacubitril/valsartan (Entresto) in real life: an observational study in a hospital centre." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.172.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Sacubitril"

1

Liu, Xiaofang, and Dichuan Liu. Effects of the sacubitril/valsartan on cardiac remodeling in patients with Acute Myocardial Infarction: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.7.0044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yang, Xinyue, Jingjing Jin, Meijuan Cheng, Jinsheng Xu, and Yaling Bai. The Role of Sacubitril/Valsartan in Abnormal Renal Function Patients Combined with Heart Failure: A Meta-Analysis and Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.12.0037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Yuanping, Lili Jin, and Peihong Huang. Efficacy and safety of Shexiang Baoxin pill compared with sacubitril/valsartan in the treatment of heart failure: a protocol for a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.11.0097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Sacubitril' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography